- Home
- CLDX vs AB Comparison
CLDX vs AB Comparison
Compare CLDX & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLDX | AB |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.4B |
| IPO Year | 1995 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CLDX | AB |
|---|---|---|
| Price | $31.09 | $35.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | ★ $63.07 | $39.57 |
| AVG Volume (30 Days) | ★ 1.8M | 309.3K |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 9.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | $19.74 | N/A |
| Revenue Next Year | $438.11 | $8.01 |
| P/E Ratio | ★ N/A | $13.85 |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $22.10 | $34.58 |
| 52 Week High | $45.14 | $44.11 |
Technical Indicators
Market Signals| Indicator | CLDX | AB |
|---|---|---|
| Relative Strength Index (RSI) | 30.11 | 38.52 |
| Support Level | $28.82 | N/A |
| Resistance Level | $31.80 | $37.70 |
| Average True Range (ATR) | 2.09 | 0.56 |
| MACD | -0.29 | -0.08 |
| Stochastic Oscillator | 5.78 | 24.88 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (40%), and private (18%) clients through products that include mutual funds, hedge funds, and separately managed accounts. At the end of July 2026, the company had $909.0 billion in managed assets, composed primarily of fixed-income (35% of AUM) and equity (40%) strategies, with other investments (including asset allocation services and certain other alternative investments) accounting for the remainder.